Urogen Pharma earnings date
Urogen Pharma (UR8) Q3 2026 Earnings Report
DE:UR8 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.03
- Consensus EPS
- EUR 0.09
- Beat/Miss
- Missed by -EUR 0.12
- One Year Ago EPS
- -EUR 0.62
DE:UR8 Q3 2026 Revenue Results
- Actual Revenue
- EUR 79.69M
- Expected Revenue
- EUR 80.51M
- Beat/Miss
- Missed by -EUR 819.25K
- YoY Revenue Growth
- +223.85%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- Before Open
- Conference Call
- Wednesday, November 4, 2026
Urogen Pharma's next earnings date is estimated for March 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly constructive, led by 35% sequential Zosturi revenue growth, expanding prescriber and repeat-use metrics, major UGN-103 regulatory progress, pipeline advancement, improved financial results, and management's expectation of profitability and positive cash flow in the fourth quarter. The principal challenges were Jelmyto revenue pressure from a one-time adjustment and clinical-trial competition, elevated operating expenses, adoption barriers, and near-term seasonality. Highlights significantly outweighed lowlights.
For 2026, UroGen updated Jelmyto net product revenue guidance to approximately $90 million, is not issuing full-year Zosturi guidance, and is maintaining full year operating expense guidance of $260 million to $270 million including $20 million to $24 million of noncash share based compensation, with operating expenses expected to land toward the upper end of the guidance range; the company expects quarter over quarter revenue growth for Zosturi in the fourth quarter of 26, is comfortable with where consensus sits for the full year for Zosturi, and anticipates achieving profitability and generating positive cash flow in the fourth quarter of 26. For 2027, the company is not issuing guides for Zosturi, although it said growing $15 to $20 million this year is a reasonable framework, and described Jelmyto as likely to be within that 100 to 150 range long term.
- Strong Zosturi Revenue GrowthZosturi generated $68 million in net product revenue in the third quarter, representing 35% sequential quarter-over-quarter growth. Management said increasing repeat utilization, broader physician adoption, and continued expansion into community practices are strengthening the commercial trends.
- Expansion of Zosturi Prescriber Base and Repeat UseAs of September 30, 2026, UroGen had over 1.5 thousand activated accounts. Unique prescribers grew to 662 from 452 in the second quarter. Management stated that repeat prescribers represented 50% of total writers, up from 45% in the second quarter and 40% in Q1, and expected the number of repeat writers to continue growing.
- Community Practice AdoptionCommunity practices accounted for the majority of Zosturi utilization, with the site-of-care mix remaining relatively consistent with the second quarter. Management said approximately 70% of the addressable market resides in community practices and identified deeper penetration in this setting as a significant opportunity.
- Broad Zosturi Patient Use and Primary-Therapy AdoptionManagement said claims data showed Zosturi usage across patients treated after one, two, three, four, five, and even 20 or 40 TURBTs. Based on anecdotal claims-database information, more than 60% of use was as a primary therapy, with adjuvant use declining to a little less than 40%.
- Zosturi Clinical DifferentiationZosturi was described as the first and only FDA-approved medicine for adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer and as a primary surgery-free treatment with a defined six-week course and no maintenance. Management stated that it does not require TURBT as part of the treatment regimen.
- Zosturi Demand Resilience and Near-Term Growth OutlookAlthough the company observed summer seasonality for a short period, management said Zosturi bounced back quickly and that growth in new prescribers and patient starts more than offset the seasonal dynamics. The company expects quarter-over-quarter revenue growth in the fourth quarter despite a typical holiday-related slowdown.
- UGN-103 Regulatory ProgressThe FDA accepted the UGN-103 NDA for review in October after its submission in August and assigned a PDUFA goal date of June 14, 2027. Management said the application is supported by Phase 3 Utopia results that were generally consistent with the three-month complete response and six-month duration of response observed in the pivotal ENVISION trial.
- UGN-103 Patent Protection and Commercial PlanningA newly issued patent listed in the FDA Orange Book is expected to provide coverage into July 2044 for both Zosturi and, if approved, UGN-103 for the treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer without TURBT. If approved in 2027, UroGen intends to apply for a permanent J-code by the July 1 quarterly submission deadline, targeting a January 1, 2028 effective date and a full commercial launch in 2028.
- UGN-103 Lifecycle ExpansionUroGen plans to initiate a randomized Phase 3 trial in the fourth quarter evaluating UGN-103 as adjuvant therapy in recurrent papillary-only, high-risk non-muscle-invasive bladder cancer patients who previously received BCG. The company also plans a nonregistrational trial in newly diagnosed intermediate-risk patients to characterize safety and clinical activity.
- Broader Pipeline AdvancementThe Phase 3 UGN-104 trial for low-grade upper tract urothelial carcinoma continued to progress, with enrollment expected to be completed by the end of 2026 or early 2027. UGN-501 received FDA IND clearance in July, the first patient was dosed in its Phase 1 trial, and initial clinical data are expected in 2027.
- IntraGel Strategic CollaborationThe strategic collaboration, licensing option, and equity investment agreement with IntraGel provides access to its biodegradable sustained-release platform and the opportunity to develop up to three new oncology products. It also provides an exclusive option to acquire worldwide rights to IntraGel's cisplatin-gel-based Phase 2-ready therapy for advanced head and neck cancer.
- Jelmyto Long-Term Clinical DurabilityFinal five-year follow-up results from the Phase 3 OLYMPUS trial showed that among all 41 patients who achieved a complete response, the median duration of response was 47.8 months. Among the 20 patients in the long-term follow-up study, 75% remained event-free at the last assessment after a median follow-up of 53.3 months, the median duration of response had not been reached, and no progression to high-grade disease was observed.
- Revenue Growth and Reduced Net LossTotal third-quarter revenue was $89 million, compared with $27.5 million in the third quarter of 2025, driven by the continued commercial launch of Zosturi. Net loss improved to $1.5 million, or $0.03 per basic and diluted share, from $33.3 million, or $0.69 per share, in the prior-year quarter.
- Cash Position and Expected ProfitabilityAs of September 30, 2026, UroGen had $90.5 million in cash, cash equivalents, and marketable securities, plus $117 million in accounts receivable. Management said it remained confident in funding the business through profitability with existing capital resources and anticipated achieving profitability and generating positive cash flow in the fourth quarter of 2026.
DE:UR8 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 18, 2027 | 2026 (Q4) | 0.35- | -0.48 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.09-0.03 | -0.62 | 95.65% (+0.59) | |
| Aug 05, 2026 | 2026 (Q2) | -0.24-0.25 | -0.94 | 73.33% (+0.69) | |
| May 06, 2026 | 2026 (Q1) | -0.43-0.42 | -0.82 | 48.91% (+0.40) | |
| Mar 02, 2026 | 2025 (Q4) | -0.45-0.48 | -0.72 | 32.50% (+0.23) | |
| Nov 06, 2025 | 2025 (Q3) | -0.62-0.62 | -0.49 | -25.45% (-0.13) | |
| Aug 07, 2025 | 2025 (Q2) | -0.77-0.94 | -0.81 | -15.38% (-0.13) | |
| May 12, 2025 | 2025 (Q1) | -0.72-0.82 | -0.87 | 5.15% (+0.04) | |
| Mar 10, 2025 | 2024 (Q4) | -0.64-0.72 | -0.64 | -11.11% (-0.07) | |
| Nov 06, 2024 | 2024 (Q3) | -0.73-0.49 | -0.61 | 19.12% (+0.12) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

